Table 1.
Characteristic | Combination therapyb | Step-up therapyc | ETN proximate switchersd | ETN remote switcherse | MTX add-onf | ETN only |
---|---|---|---|---|---|---|
All patients (n = 1681), n (%) | 258 (15.3) | 892 (53.1) | 86 (5.1) | 86 (5.1) | 144 (8.6) | 215 (12.8) |
JIAg category, n (%)h | ||||||
Oligoarthritis (n = 366) | 34 (9.3) | 184 (50.3) | 34 (9.3) | 32 (8.7) | 29 (7.9) | 53 (14.5) |
Persistent (n = 159) | 13 (8.2) | 74 (46.5) | 11 (6.9) | 13 (8.2) | 12 (7.5) | 36 (22.6) |
Extended (n = 178) | 15 (8.4) | 99 (55.6) | 18 (10.1) | 19 (10.7) | 15 (8.4) | 12 (6.7) |
Unknown (n = 29) | 6 (20.7) | 11 (37.9) | 5 (17.2) | 0 | 2 (6.9) | 5 (17.2) |
Polyarthritis (RF-)i (n = 736) | 113 (15.4) | 437 (59.4) | 36 (4.9) | 31 (4.2) | 57 (7.7) | 62 (8.4) |
Polyarthritis (RF+) (n = 208) | 49 (23.6) | 109 (52.4) | 3 (1.4) | 7 (3.4) | 23 (11.1) | 17 (8.2) |
Psoriatic arthritis (n = 134) | 29 (21.6) | 59 (44.0) | 4 (3.0) | 5 (3.7) | 12 (9.0) | 25 (18.7) |
Enthesitis related arthritis (n = 163) | 23 (14.1) | 65 (39.9) | 7 (4.3) | 4 (2.5) | 13 (8.0) | 51 (31.3) |
Systemic arthritis (n = 40) | 4 (10.0) | 23 (57.5) | 1 (2.5) | 2 (5.0) | 9 (22.5) | 1 (2.5) |
Undifferentiated arthritis (n = 34) | 6 (17.6) | 15 (44.1) | 1 (2.9) | 5 (14.7) | 1 (2.9) | 6 (17.6) |
a In patients with at least 1 study visit 6 months after starting etanercept; b Combination therapy = methotrexate (MTX) started concurrently with etanercept (ETN); c step-up therapy = MTX started > 1 month prior to ETN and continued > 1 month after ETN initiation; d proximate switchers = MTX started> 1 month prior to ETN and discontinued within 1 month prior to or after ETN; e ETN remote switchers = MTX discontinued > 1 month prior to start of ETN; f MTX add-on = MTX started > 1 month after starting ETN; gJIA juvenile idiopathic arthritis; h Denominator for percentage calculations is the n for that category of JIA; iRF rheumatoid factor